Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21699863 | 1.00 | KLKB1 (0.83) | KLKB1KLK1 | |
| SCHEMBL17268102 | 0.95 | KLKB1 (0.91) | KLKB1KLK1 | |
| SCHEMBL21699873 | 0.95 | KLKB1 (0.91) | KLKB1KLK1 | |
| SCHEMBL23517198 | 0.95 | KLKB1 (0.91) | KLKB1KLK1 | |
| SCHEMBL14555079 | 0.95 | KLKB1 (0.91) | KLKB1KLK1 | |
| Hydrochloric Acid SCHEMBL14485639 | 0.94 | KLKB1 (0.89) | KLKB1KLK1 | |
| Hydrochloric Acid SCHEMBL20136153 | 0.94 | KLKB1 (0.89) | KLKB1KLK1 | |
| SCHEMBL15901297 | 0.91 | KLKB1 (0.83) | KLKB1KLK1 | |
| SCHEMBL14488775 | 0.91 | KLKB1 (0.83) | KLKB1KLK1 | |
| SCHEMBL21669910 | 0.90 | KLKB1 (0.88) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401390-A1 | TREATMENTS OF DIABETIC MACULAR EDEMA AND IMPAIRED VISUAL ACUITY | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401390-A1 | TREATMENTS OF DIABETIC MACULAR EDEMA AND IMPAIRED VISUAL ACUITY | AQP1, VEGFA, AQP3 | KLKB1 222/4885KLK1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.